Skip to content

Released Mar 6, 2017, after the close

10-K filed Mar 6, 2017, 65 days after period end · 0001144204-17-012930

Q4 2016 · 10-K
Revenue—
Net Income-$2.97MN/M vs Q4 2015N/M vs Q3 2016
EPS Diluted-$0.16N/M vs Q4 2015N/M vs Q3 2016
Operating Income-$3,015,090N/M
Operating Cash Flowderived-$2,547,068N/M
Free Cash Flowderived-$2,547,068N/M

What the release said

The release

Same quarter

MetricQ4 2016Q4 2015Q4 2014derived from reported figuresQ4 2013derived from reported figures
Net Income-$2.97M-$4.63M-$4.04M-$4.39M
EPS Diluted-$0.16-$0.25——

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR